Advertisement

Doklady Biochemistry and Biophysics

, Volume 478, Issue 1, pp 14–17 | Cite as

Expression Profiles of Genes—Potential Therapy Targets—and Their Relationship to Survival in Renal Cell Carcinoma

  • N. V. Apanovich
  • M. V. Peters
  • P. V. Apanovich
  • B. Sh. Kamolov
  • V. B. Matveev
  • E. K. Ginter
  • A. V. Karpukhin
Biochemistry, Biophysics, and Molecular Biology

Abstract

The main mechanisms of pathogenesis of clear cell renal cell carcinoma (CCRCC) are realized through the PI3K–AKT–mTOR and Ras–RAF–ERK signaling pathways. Targeted therapy is directed primarily at the genes and their encoded products that are components of these pathways. The levels of expression and coexpression of target genes were determined, and the difference in the functioning of the genes of one of the two major signaling pathways in tumors of CCRCC patients with different life duration (more and less than 3.5 years) and the relationship of the VEGFA gene expression level with the life duration was revealed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davydov, M.I. and Aksel’, E.M., Statistika zlokachestvennykh novoobrazovanii v Rossii i stranakh SNG v 2012 g. (Malignancies in Russia and CIS in 2012), Moscow: Izd. gruppa RONTs, 2014.Google Scholar
  2. 2.
    Najjar, Y.G. and Rini, B.I., Ther. Adv. Med. Oncol., 2012, vol. 4, no. 4, pp. 183–194.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Donalisio da Silva, R., Gustafson, D., Nogueira, L., et al., J. Kidney Cancer VHL, 2014, vol. 1, no. 6, pp. 63–73.CrossRefGoogle Scholar
  4. 4.
    Reynier, F., Petit, F., Paye, M., et al., PLoS ONE, 2011, vol. 6, no. 10, p. e24828. doi 10.1371CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Richiardi, J., Altmann, A., Milazzo, A., et al., Science, 2015, vol. 348, no. 6240, pp. 1241–1244.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Shibuya, M., Genes Cancer, 2011, vol. 2, no. 12, pp. 1097–1105.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ball, S.G., Shuttleworth, C.A., and Kielty, C.M., J. Cell Biol., 2007, vol. 177, no. 3, pp. 489–500.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Pópulo, H., Lopes, J.M., and Soares, P., Int. J. Mol. Sci., 2012, vol. 13, no. 2, pp. 1886–1918.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Carracedo, A., Li, Ma., Teruya-Feldstein, J., et al., J. Clin. Invest., 2008, vol. 118, no. 9, pp. 3065–3074.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Voroshilova, E.A., Apanovich, N.V., Nosov, D.A., et al., Onkourologiya, 2015, vol. 11, no. 4, pp. 34–41.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2018

Authors and Affiliations

  • N. V. Apanovich
    • 1
  • M. V. Peters
    • 2
  • P. V. Apanovich
    • 1
  • B. Sh. Kamolov
    • 2
  • V. B. Matveev
    • 2
    • 3
  • E. K. Ginter
    • 1
  • A. V. Karpukhin
    • 1
  1. 1.Research Centre for Medical GeneticsМоscowRussia
  2. 2.Blokhin Russian Cancer Research CenterMinistry of Healthcare of the Russian FederationMoscowRussia
  3. 3.Faculty of Fundamental MedicineMoscow State UniversityMoscowRussia

Personalised recommendations